Placebo: The Power of the Human Mind Confounds Medical Research
Angelman syndrome, which creates a variety of developmental problems, has proven a challenge for researchers on that accountWe don’t often hear about researchers crying but when researchers at Ovid Therapeutics heard the test results for their drug, gaboxadol, they couldn’t help it. They were testing the sleep-inducing drug to help with the symptoms of Angelman Syndrome, a rare neurogenetic disorder that appears in infancy. It results in a variety of developmental problems such as walking and balance disorders, inability to speak or sleep properly, gastrointestinal issues, and seizures. It affects people in different ways and to different degrees. Notably, those who cope with Angelman smile and laugh a lot and have a normal lifespan. The OVID team had high hopes for gaboxadol in August of this year because even improving the quality of sleep would help sufferers Read More ›
